Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension, multicenter, double-blind, parallel-dose trial of plant cell–expressed recombinant human glucocerebrosidase (prGCD) in Gaucher disease
2008-005826-35Phase 3Completed
- Sponsor
- Protalix BioTherapeutics
- Start
- Apr 2009
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of imiglucerase in Gaucher disease (GD) (2 arms), sponsored by Protalix BioTherapeutics. Primary endpoints: Long-term safety of prGCD and Long-term efficacy of prGCD. Started Apr 2009; status: completed.
02
Drugs
imiglucerase
03
Conditions
Gaucher disease (GD)
Beyond the preview
Go deeper on 2008-005826-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005826-35.